The number of HIV-infected individuals decreases by half in India: Impact on the global epidemiology of HIV/AIDS

Future HIV Therapy

Volumn 2, Issue 5, 2008, Pages 395-398

  Venkatesh, Kartik K ^a   Kumarasamy, Nagalingeswaran ^b  

^a BROWN UNIVERSITY   (United States)

^b YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CONDOM; DISEASE SURVEILLANCE; EDITORIAL; EPIDEMIC; HEALTH CARE COST; HEALTH PROGRAM; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INDIA; POPULATION RESEARCH; PREVALENCE; RISK FACTOR; SEXUAL BEHAVIOR; SOCIOECONOMICS; VIRUS TRANSMISSION;

EID: 55349135515     PISSN: 17469600     EISSN: None     Source Type: Journal    
DOI: 10.2217/17469600.2.5.395     Document Type: Editorial

References (8)

1. Dandona L, Lakshmi V, Sudha T, Kumar GA, Dandona R: A population-based study of human immunodeficiency virus in south India reveals major differences from sentinel surveillance-based estimates. BMC Med. 13(4), 31 (2006).
2. Dandona L, Lakshmi V, Kumar GA, Dandona R: Is the HIV burden in India being overestimated? BMC Public Health 20(6), 308 (2006).
3. Kumar R, Jha P, Arora P et al.: International Studies of HIV/AIDS (ISHA) Investigators. Trends in HIV-1 in young adults in south India from 2000 to 2004: a prevalence study. Lancet 367(9517), 1164-1172 (2004).
4. Steinbrook R: HIV in India: a complex epidemic. N. Engl. J. Med. 356(11), 1089-1093 (2007).
5. Dandona L, Sivan YS, Jyothi MN, Bhaskar VS, Dandona R: The lack of public health research output from India. BMC Public Health 25(4), 55 (2004).
6. Dandona L, Dandona R: Drop of HIV estimate for India to less than half. Lancet 370(9602), 1811-1813 (2007).
7. UNAIDS. From know more to no more AIDS. Veerendra Printers, New Delhi, India (2004).
8. Dandona L: Enhancing the evidence base for HIV/AIDS control in India. Natl Med. J. India 17(3), 160-166 (2004).